[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI20000343A - A process for the preparation of therapeutically useful pyrrolopyrimidines - Google Patents

A process for the preparation of therapeutically useful pyrrolopyrimidines Download PDF

Info

Publication number
FI20000343A
FI20000343A FI20000343A FI20000343A FI20000343A FI 20000343 A FI20000343 A FI 20000343A FI 20000343 A FI20000343 A FI 20000343A FI 20000343 A FI20000343 A FI 20000343A FI 20000343 A FI20000343 A FI 20000343A
Authority
FI
Finland
Prior art keywords
pyrrolopyrimidines
preparation
therapeutically useful
stress
compounds
Prior art date
Application number
FI20000343A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI109799B (en
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI20000343A publication Critical patent/FI20000343A/en
Application granted granted Critical
Publication of FI109799B publication Critical patent/FI109799B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The compounds of the formulawherein R1, R2, R3, R4, R5 and R6 are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of stress and anxiety related, and other disorders.
FI20000343A 1992-12-17 2000-02-16 Process for the preparation of therapeutically useful 4- (substituted) -2,5-dialkyl-7- (di- or trisubstituted) -phenyl-7H-pyrrolo [2,3-d] pyrimidine derivatives FI109799B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99176492A 1992-12-17 1992-12-17
US99176492 1992-12-17

Publications (2)

Publication Number Publication Date
FI20000343A true FI20000343A (en) 2000-02-16
FI109799B FI109799B (en) 2002-10-15

Family

ID=25537532

Family Applications (2)

Application Number Title Priority Date Filing Date
FI935585A FI935585A (en) 1992-12-17 1993-12-13 pyrrolopyrimidines
FI20000343A FI109799B (en) 1992-12-17 2000-02-16 Process for the preparation of therapeutically useful 4- (substituted) -2,5-dialkyl-7- (di- or trisubstituted) -phenyl-7H-pyrrolo [2,3-d] pyrimidine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI935585A FI935585A (en) 1992-12-17 1993-12-13 pyrrolopyrimidines

Country Status (24)

Country Link
US (1) US6765008B1 (en)
EP (1) EP0674641B1 (en)
JP (1) JP2895961B2 (en)
KR (2) KR0173172B1 (en)
CN (1) CN1038131C (en)
AT (1) ATE177101T1 (en)
BR (1) BR9307646A (en)
CA (1) CA2150016C (en)
CZ (1) CZ286892B6 (en)
DE (1) DE69323768T2 (en)
DK (1) DK0674641T3 (en)
ES (1) ES2128544T3 (en)
FI (2) FI935585A (en)
GR (1) GR3029561T3 (en)
HU (3) HU225053B1 (en)
IL (5) IL119461A (en)
MY (1) MY131458A (en)
NO (1) NO306678B1 (en)
NZ (1) NZ258690A (en)
PL (1) PL176526B1 (en)
RU (1) RU2124015C1 (en)
TW (1) TW295585B (en)
WO (1) WO1994013676A1 (en)
ZA (1) ZA939271B (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
AU692484B2 (en) 1993-10-12 1998-06-11 Du Pont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
DE69533284T2 (en) * 1994-04-29 2005-07-21 Pfizer Inc. NEW CYCLIC AND ACYCLIC AMIDS FOR INCREASING NEUROTRANSMITTER DISTRIBUTION
ATE159257T1 (en) * 1994-05-03 1997-11-15 Ciba Geigy Ag PYRROLOPYRIMIDE DERIVATIVES WITH ANTIPROLIFERATIVE EFFECT
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
ATE182332T1 (en) * 1994-06-16 1999-08-15 Pfizer PYRAZOLO AND PYRROLOPYRIDINES
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
CA2194756A1 (en) * 1995-05-12 1996-11-14 Jun Yuan Novel deazapurine derivatives; a new class of crf1 specific ligands
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
ES2203642T3 (en) * 1995-06-07 2004-04-16 Pfizer Inc. HETEROCICLIC PYRIMIDINE DERIVATIVES WITH CONDENSED RINGS.
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
EP0778277B1 (en) * 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
WO1997029110A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Thiophenopyrimidines
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
NZ331647A (en) * 1996-03-26 2000-03-27 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
CA2257222C (en) * 1996-06-06 2002-08-20 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
KR100548853B1 (en) * 1996-07-24 2006-02-02 브리스톨-마이어스 스퀴브 파마 컴파니 Azolo Triazines and Pyrimidines
DK0920429T3 (en) * 1996-08-06 2003-05-12 Pfizer Substituted pyrido or pyrimido-containing, 6.6- or 6,7-bicyclic derivatives
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
JP2001502300A (en) 1996-09-16 2001-02-20 デュポン ファーマシューティカルズ カンパニー Pyrazinones and triazinones and their derivatives
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
US5972945A (en) * 1997-06-13 1999-10-26 Neurogen Corporation 2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands
US6313141B1 (en) 1997-06-13 2001-11-06 Neurogen Corporation 2-aminoalkylaminoquinolines as dopamine D4 ligands
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
EP1068207A1 (en) * 1998-04-02 2001-01-17 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES
JP2002510687A (en) 1998-04-02 2002-04-09 ニューロゲン コーポレイション Aminoalkyl-substituted pyrrolo [2,3-B] pyridine and pyrrolo [2,3-D] pyrimidine derivatives: modulators of the CRF1 receptor
AU3220299A (en) 1998-04-02 1999-10-25 Neurogen Corporation Substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives:selective neuropeptide y receptor ligands
US6147085A (en) * 1999-04-01 2000-11-14 Neurogen Corporation Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IL139787A0 (en) * 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
CA2334671A1 (en) 1998-06-09 1999-12-16 Neurogen Corporation Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands
TR200102178T2 (en) 1998-11-12 2002-01-21 Neurocrine Biosciences, Inc. CRF receptor antagonists and related methods.
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE225349T1 (en) 1998-11-12 2002-10-15 Neurocrine Biosciences Inc CRF RECEPTOR ANTAGONISTS AND RELATED METHODS
KR20010102544A (en) * 1999-03-11 2001-11-15 우에하라 아끼라 Carbamoyl Tetrahydropyridine Derivatives
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CA2379640C (en) 1999-09-30 2006-11-28 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
AU779995B2 (en) 2000-01-18 2005-02-24 Pfizer Products Inc. Corticotropin releasing factor antagonists
KR20030016222A (en) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 Preventives/remedies for postoperative stress
US6613901B2 (en) 2000-03-08 2003-09-02 Neurogen Corporation 2-aminoalkylaminoquinolines as dopamine D4 ligands
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
OA13295A (en) * 2000-12-01 2007-04-13 Osi Pharm Inc Compounds specific to adenosine A1, A2a, and A3 receptor and uses thereof.
UA74228C2 (en) * 2000-12-01 2005-11-15 Осі Фармасьютікалз, Інк. DERIVATIVES OF PYRROLO[2,3-d]PYRIMIDINE, SPECIFIC TO ADENOSINE A<sub>1, A</sub><sub>2А AND A</sub><sub>3 RECEPTORS, A METHOD FOR PRODUCING THEREOF AND A PHARMACEUTICAL COMPOSITION
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
NZ529333A (en) 2001-04-27 2005-01-28 Eisai Co Ltd Pyrazolo[1,5-a]pyridines and medicines containing the same
SK13752003A3 (en) 2001-05-14 2004-11-03 Bristol Myers Squibb Pharma Co Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DK1450811T3 (en) 2001-11-30 2010-02-15 Osi Pharm Inc Compounds specific for adenosine A1 and A3 receptors and uses thereof
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
CN1816551A (en) 2001-12-20 2006-08-09 Osi药物公司 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
DE10163991A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
NZ538860A (en) 2002-10-22 2006-07-28 Eisai Co Ltd 7-Phenyl pyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
GR1004664B (en) * 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
JP2006513257A (en) 2002-12-13 2006-04-20 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Pregabalin derivatives for treating fibromyalgia and other disorders
AR042667A1 (en) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd PIRROLOPIRIMIDINE AND PIRROLOPIRIDINE DERIVATIVES REPLACED WITH A CYCLIC AMINO GROUP
US20060058217A1 (en) * 2003-01-21 2006-03-16 White Hillary D Compositions and methods for treatment of ovarian cancer
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
ATE418555T1 (en) 2003-04-09 2009-01-15 Biogen Idec Inc A2A ADENOSIN RECEPTOR ANTAGONISTS
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
RU2367663C2 (en) 2004-01-06 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Pyrrolopyrimidine and pyrrolotriazine derivatives
JP2007517793A (en) 2004-01-06 2007-07-05 大正製薬株式会社 Thienopyrimidine and thienopyridine derivatives substituted by cyclic amino groups
US20070270588A1 (en) * 2004-03-05 2007-11-22 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine Derivatives
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
JP2007161585A (en) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivative substituted with cyclic amino group
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
PE20061298A1 (en) * 2005-04-22 2006-12-24 Wyeth Corp DIHYDROBENZOFURAN-DERIVED COMPOUNDS AS AGONISTS OF THE SEROTONIN 5-HT2C RECEPTOR
GT200600165A (en) * 2005-04-22 2007-03-14 DIHYDROBENZOFURAN DERIVATIVES AND USES OF THE SAME
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
EP1998773A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment of depression
JP2009531443A (en) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド Inhibition of alpha-synuclein toxicity
CA2662000C (en) 2006-09-20 2013-01-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
EP2094709B1 (en) 2006-09-20 2010-09-15 Eli Lilly And Company Thiazole pyrazolopyrimidines as crf1 receptor antagonists
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2008157302A2 (en) * 2007-06-13 2008-12-24 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
SI2266990T1 (en) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. 3-PHENYLPYRAZOLOS5,1-bCTHIAZOLE COMPOUND
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
AR078521A1 (en) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd PIRAZOLOTIAZOL COMPOUND
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
SI2958921T1 (en) 2013-02-22 2017-12-29 Pfizer Inc. Pyrrolo (2, 3 -d)pyrimidine derivatives as inhibitors of janus kinases (jak)
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
JP6585158B2 (en) 2014-08-12 2019-10-02 ファイザー・インク Pyrrolo [2,3-d] pyrimidine derivatives useful for the inhibition of Janus kinase
US10344032B2 (en) 2014-09-17 2019-07-09 Pécsi Tudományegyetem Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
MA42023B2 (en) * 2015-07-20 2022-01-31 Genzyme Corp Colony Stimulating Factor-1 Receptor (csf-1r) Inhibitors
SG10202106949XA (en) * 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
JP7398963B2 (en) 2017-08-14 2023-12-15 スプルース バイオサイエンシズ インコーポレイテッド Corticotropin-releasing factor receptor antagonist
IL300478A (en) 2020-08-12 2023-04-01 Spruce Biosciences Inc Methods and compositions for treating polycystic ovary syndrome
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818676A1 (en) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg SUBSTITUTED 5,6-DIMETHYLPYRROLO 2,3-D PYRIMIDINE, THE METHOD FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT
DE3145287A1 (en) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo[2,3-d]pyrimidines, process for their preparation and their use as medicaments
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5002950A (en) * 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US5153352A (en) 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
CA2051012C (en) 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants
GB9022644D0 (en) 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
ES2092182T3 (en) 1992-08-10 1996-11-16 Volkswagen Ag EXCHANGE DEVICE FOR A GEARBOX.

Also Published As

Publication number Publication date
IL119462A0 (en) 1997-01-10
ZA939271B (en) 1995-06-12
HU9303515D0 (en) 1994-04-28
PL176526B1 (en) 1999-06-30
TW295585B (en) 1997-01-11
IL119462A (en) 2000-02-29
NO306678B1 (en) 1999-12-06
JPH07509726A (en) 1995-10-26
JP2895961B2 (en) 1999-05-31
CN1097758A (en) 1995-01-25
CN1038131C (en) 1998-04-22
KR0173172B1 (en) 1999-02-01
IL107897A0 (en) 1994-04-12
MY131458A (en) 2007-08-30
FI935585A (en) 1994-06-18
FI935585A0 (en) 1993-12-13
GR3029561T3 (en) 1999-06-30
HU225053B1 (en) 2006-05-29
NO952398D0 (en) 1995-06-16
WO1994013676A1 (en) 1994-06-23
DK0674641T3 (en) 1999-09-27
CZ158495A3 (en) 1996-01-17
CA2150016A1 (en) 1994-06-23
RU2124015C1 (en) 1998-12-27
EP0674641A1 (en) 1995-10-04
CZ286892B6 (en) 2000-07-12
AU690090B2 (en) 1998-04-23
NZ258690A (en) 1997-01-29
RU95113862A (en) 1997-06-10
FI109799B (en) 2002-10-15
HU0103927D0 (en) 2001-12-28
HUT70505A (en) 1995-10-30
CA2150016C (en) 2000-02-08
IL119461A0 (en) 1997-01-10
US6765008B1 (en) 2004-07-20
PL309357A1 (en) 1995-10-02
HU221587B (en) 2002-11-28
BR9307646A (en) 1999-05-25
DE69323768D1 (en) 1999-04-08
AU5666494A (en) 1994-07-04
NO952398L (en) 1995-06-16
ATE177101T1 (en) 1999-03-15
DE69323768T2 (en) 1999-07-01
EP0674641B1 (en) 1999-03-03
IL119461A (en) 2000-02-29
KR19990067704A (en) 1999-08-25
KR950704320A (en) 1995-11-17
ES2128544T3 (en) 1999-05-16
IL107897A (en) 2001-01-28

Similar Documents

Publication Publication Date Title
FI20000343A (en) A process for the preparation of therapeutically useful pyrrolopyrimidines
DE69510940D1 (en) PYRAZOLO AND PYRROLOPYRIDINE
MY131382A (en) Pyrazoles and pyrazolopyrimidines
MY115300A (en) Pyrazolopyrimidines.
ES2127946T3 (en) DIAZABYCLIC NEUROCININE ANTAGONISTS.
GB9416442D0 (en) Therapeutic heterocycles
IL114061A0 (en) Methods of administering crf antagonists

Legal Events

Date Code Title Description
MA Patent expired